Future Therapies of Wet Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population, and the prevalence of the disease increases exponentially with every decade after the age of 50 years. While VEGF inhibitors are promising drugs for treating patients with ocular neovascularization, t...
Main Authors: | Ishikawa, Makoto, Jin, Daisuke, Sawada, Yu, Abe, Sanae, Yoshitomi, Takeshi |
---|---|
Format: | Online |
Language: | English |
Published: |
Hindawi Publishing Corporation
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354726/ |
Similar Items
-
Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
by: Garba, Adinoyi O., et al.
Published: (2010) -
Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
by: Adinoyi O. Garba, et al.
Published: (2010-01-01) -
Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
by: Adinoyi O. Garba, et al.
Published: (2010-12-01) -
Imaging of Wet Age-Related Macular Degeneration
by: Kenan, Damer
Published: (2016) -
Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
by: García-Layana, Alfredo, et al.
Published: (2015)